ICER Value Framework Update Reaffirms Support For Real-World Evidence
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
You may also be interested in...
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.
Future value assessments will include ‘hypothetical’ scenarios in which downstream medical savings will be shared between the health care system and the treatment developer.
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.